Decoding the metabolic landscape of Parkinson’s disease: dansylated urinary amines and phenols submetabolomes for signature profiling and biomarker discovery
Case-control study reveals distinct urinary metabolic signatures in Parkinson's disease, suggesting non-invasive diagnostic utility.
Key Points
To identify non-invasive diagnostic biomarkers for Parkinson's disease by profiling urinary amine and phenol submetabolomes using an advanced mass spectrometry workflow.
Analyzed urine samples from 21 patients with Parkinson's disease, 21 patients with Alzheimer's disease, and 21 healthy controls using dansylation coupled to trapped ion mobility spectrometry–quadrupole time-of-flight mass spectrometry (TIMS-Q-TOF-MS).
Applied partial least squares discriminant analysis (PLS-DA) with significance thresholds of VIP > 1.2 and p < 0.05 to identify differentially abundant metabolites.
Evaluated diagnostic accuracy using receiver operating characteristic (ROC) curve analysis.
Annotated 196 metabolites and identified 47 differentially abundant metabolites in Parkinson's disease enriched in cysteine/methionine, pyrimidine, and tryptophan metabolic pathways.
Parkinson's disease exhibited elevated dopamine 3-O-sulfate and decreased tryptophan alongside its hydroxylated derivatives.
A three-metabolite signature (4-amino-1-piperidinecarboxylic acid, dopamine 3-O-sulfate, methylacetylenic putrescine) discriminated Parkinson's disease from healthy controls with an AUC of 0.923 (95% CI: 0.828–0.986).